Document is current
Any future updates will be listed below
-
Authors
Battin, Claire
De Sousa Linhares, Annika
Leitner, Judith
Grossmann, Anna
Lupinek, Daniela
Izadi, Shiva
Castilho, Alexandra
Waidhofer-Söllner, Petra
Grabmeier-Pfistershammer, Katharina
Stritzker, Jochen
Steinberger, Peter
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 5 October 2022
Accepted: 22 May 2023
First Online: 13 June 2023
Declarations
:
: CB, ADSL, AG, DL and JS are former employees of Themis Bioscience GmbH, asubsidiary of Merck & Co, Inc., Rahway, New Jersey, USA. ADSL, DL, PS and JS are inventors on the patent application TM 5703-01EP that covers the use of 4-1BBL ectodomains for immunomodulation. All other authors declare to have no other commercial or financial conflict of interest.
: The in vivo experiments were carried out by TransCure bioServices SAS (Archamps, France) and approval was obtained from the local ethic committee (CELEAG) as well as the internal animal care and use committee of Merck & Co, Inc., Rahway, New Jersey, USA (protocol number: S-2024–301194).
